nodes	percent_of_prediction	percent_of_DWPC	metapath
Toremifene—CYP1A1—Dacarbazine—sarcoma	0.215	0.266	CbGbCtD
Toremifene—CYP1A2—Dacarbazine—sarcoma	0.0958	0.119	CbGbCtD
Toremifene—CYP3A4—Thiotepa—sarcoma	0.0906	0.112	CbGbCtD
Toremifene—ABCB1—Dactinomycin—sarcoma	0.0727	0.0901	CbGbCtD
Toremifene—ABCB1—Mitoxantrone—sarcoma	0.065	0.0806	CbGbCtD
Toremifene—CYP1A2—Etoposide—sarcoma	0.0469	0.0582	CbGbCtD
Toremifene—ABCB1—Vincristine—sarcoma	0.0447	0.0555	CbGbCtD
Toremifene—ABCB1—Etoposide—sarcoma	0.041	0.0509	CbGbCtD
Toremifene—CYP3A4—Mitoxantrone—sarcoma	0.039	0.0483	CbGbCtD
Toremifene—ABCB1—Doxorubicin—sarcoma	0.028	0.0347	CbGbCtD
Toremifene—CYP3A4—Vincristine—sarcoma	0.0268	0.0333	CbGbCtD
Toremifene—CYP3A4—Etoposide—sarcoma	0.0246	0.0305	CbGbCtD
Toremifene—CYP3A4—Doxorubicin—sarcoma	0.0168	0.0208	CbGbCtD
Toremifene—Acute coronary syndrome—Vincristine—sarcoma	0.000905	0.00509	CcSEcCtD
Toremifene—Neuropathy peripheral—Vincristine—sarcoma	0.0009	0.00506	CcSEcCtD
Toremifene—Myocardial infarction—Vincristine—sarcoma	0.0009	0.00506	CcSEcCtD
Toremifene—Acute coronary syndrome—Mitoxantrone—sarcoma	0.000882	0.00495	CcSEcCtD
Toremifene—Sweating—Vincristine—sarcoma	0.00088	0.00495	CcSEcCtD
Toremifene—Myocardial infarction—Mitoxantrone—sarcoma	0.000877	0.00493	CcSEcCtD
Toremifene—Jaundice—Mitoxantrone—sarcoma	0.000872	0.0049	CcSEcCtD
Toremifene—Eye disorder—Thiotepa—sarcoma	0.000869	0.00488	CcSEcCtD
Toremifene—Sweating—Mitoxantrone—sarcoma	0.000857	0.00482	CcSEcCtD
Toremifene—Rigors—Doxorubicin—sarcoma	0.000845	0.00475	CcSEcCtD
Toremifene—Angiopathy—Thiotepa—sarcoma	0.000843	0.00474	CcSEcCtD
Toremifene—Mediastinal disorder—Thiotepa—sarcoma	0.000838	0.00471	CcSEcCtD
Toremifene—Chills—Thiotepa—sarcoma	0.000834	0.00469	CcSEcCtD
Toremifene—Arrhythmia—Thiotepa—sarcoma	0.000831	0.00467	CcSEcCtD
Toremifene—Chills—Dactinomycin—sarcoma	0.000828	0.00465	CcSEcCtD
Toremifene—Skin discolouration—Epirubicin—sarcoma	0.000825	0.00464	CcSEcCtD
Toremifene—Alopecia—Thiotepa—sarcoma	0.000822	0.00462	CcSEcCtD
Toremifene—Alopecia—Dactinomycin—sarcoma	0.000815	0.00458	CcSEcCtD
Toremifene—Mental disorder—Thiotepa—sarcoma	0.000814	0.00458	CcSEcCtD
Toremifene—Malnutrition—Thiotepa—sarcoma	0.000809	0.00455	CcSEcCtD
Toremifene—Back pain—Thiotepa—sarcoma	0.000783	0.0044	CcSEcCtD
Toremifene—Skin discolouration—Doxorubicin—sarcoma	0.000764	0.00429	CcSEcCtD
Toremifene—Vision blurred—Thiotepa—sarcoma	0.000763	0.00429	CcSEcCtD
Toremifene—Coordination abnormal—Epirubicin—sarcoma	0.000759	0.00427	CcSEcCtD
Toremifene—Angiopathy—Vincristine—sarcoma	0.000748	0.0042	CcSEcCtD
Toremifene—Pulmonary embolism—Epirubicin—sarcoma	0.000745	0.00419	CcSEcCtD
Toremifene—Hepatocellular injury—Epirubicin—sarcoma	0.000745	0.00419	CcSEcCtD
Toremifene—Mediastinal disorder—Vincristine—sarcoma	0.000743	0.00418	CcSEcCtD
Toremifene—Acute coronary syndrome—Etoposide—sarcoma	0.000733	0.00412	CcSEcCtD
Toremifene—Neuropathy peripheral—Etoposide—sarcoma	0.000729	0.0041	CcSEcCtD
Toremifene—Myocardial infarction—Etoposide—sarcoma	0.000729	0.0041	CcSEcCtD
Toremifene—Alopecia—Vincristine—sarcoma	0.000728	0.00409	CcSEcCtD
Toremifene—Jaundice—Etoposide—sarcoma	0.000725	0.00408	CcSEcCtD
Toremifene—Leukopenia—Thiotepa—sarcoma	0.000724	0.00407	CcSEcCtD
Toremifene—Mental disorder—Vincristine—sarcoma	0.000722	0.00406	CcSEcCtD
Toremifene—Chills—Mitoxantrone—sarcoma	0.00072	0.00405	CcSEcCtD
Toremifene—Leukopenia—Dactinomycin—sarcoma	0.000719	0.00404	CcSEcCtD
Toremifene—Arrhythmia—Mitoxantrone—sarcoma	0.000717	0.00403	CcSEcCtD
Toremifene—Alopecia—Mitoxantrone—sarcoma	0.000709	0.00399	CcSEcCtD
Toremifene—Hepatobiliary disease—Etoposide—sarcoma	0.000704	0.00395	CcSEcCtD
Toremifene—Coordination abnormal—Doxorubicin—sarcoma	0.000702	0.00395	CcSEcCtD
Toremifene—Back pain—Vincristine—sarcoma	0.000694	0.0039	CcSEcCtD
Toremifene—Hepatocellular injury—Doxorubicin—sarcoma	0.00069	0.00388	CcSEcCtD
Toremifene—Pulmonary embolism—Doxorubicin—sarcoma	0.00069	0.00388	CcSEcCtD
Toremifene—Dry eye—Epirubicin—sarcoma	0.000688	0.00387	CcSEcCtD
Toremifene—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—sarcoma	0.000684	0.00385	CcSEcCtD
Toremifene—Back pain—Mitoxantrone—sarcoma	0.000676	0.0038	CcSEcCtD
Toremifene—Vision blurred—Mitoxantrone—sarcoma	0.000659	0.0037	CcSEcCtD
Toremifene—Oedema—Dactinomycin—sarcoma	0.000656	0.00368	CcSEcCtD
Toremifene—Abnormal vision—Epirubicin—sarcoma	0.00065	0.00365	CcSEcCtD
Toremifene—Nervous system disorder—Thiotepa—sarcoma	0.000648	0.00364	CcSEcCtD
Toremifene—Thrombocytopenia—Thiotepa—sarcoma	0.000647	0.00363	CcSEcCtD
Toremifene—Vertigo—Vincristine—sarcoma	0.000645	0.00362	CcSEcCtD
Toremifene—Leukopenia—Vincristine—sarcoma	0.000642	0.00361	CcSEcCtD
Toremifene—Thrombocytopenia—Dactinomycin—sarcoma	0.000642	0.00361	CcSEcCtD
Toremifene—Skin disorder—Thiotepa—sarcoma	0.000642	0.00361	CcSEcCtD
Toremifene—Dry eye—Doxorubicin—sarcoma	0.000637	0.00358	CcSEcCtD
Toremifene—Anorexia—Thiotepa—sarcoma	0.00063	0.00354	CcSEcCtD
Toremifene—Leukopenia—Mitoxantrone—sarcoma	0.000626	0.00352	CcSEcCtD
Toremifene—Thrombophlebitis—Epirubicin—sarcoma	0.000625	0.00351	CcSEcCtD
Toremifene—Anorexia—Dactinomycin—sarcoma	0.000625	0.00351	CcSEcCtD
Toremifene—Eye disorder—Etoposide—sarcoma	0.000624	0.00351	CcSEcCtD
Toremifene—Angiopathy—Etoposide—sarcoma	0.000606	0.00341	CcSEcCtD
Toremifene—Mediastinal disorder—Etoposide—sarcoma	0.000602	0.00338	CcSEcCtD
Toremifene—Abnormal vision—Doxorubicin—sarcoma	0.000602	0.00338	CcSEcCtD
Toremifene—Chills—Etoposide—sarcoma	0.000599	0.00337	CcSEcCtD
Toremifene—ESR1—periosteum—sarcoma	0.000597	0.234	CbGeAlD
Toremifene—Chest pain—Mitoxantrone—sarcoma	0.000595	0.00334	CcSEcCtD
Toremifene—Alopecia—Etoposide—sarcoma	0.00059	0.00332	CcSEcCtD
Toremifene—Oedema—Vincristine—sarcoma	0.000586	0.00329	CcSEcCtD
Toremifene—Hot flush—Epirubicin—sarcoma	0.000578	0.00325	CcSEcCtD
Toremifene—Thrombophlebitis—Doxorubicin—sarcoma	0.000578	0.00325	CcSEcCtD
Toremifene—Nervous system disorder—Vincristine—sarcoma	0.000574	0.00323	CcSEcCtD
Toremifene—Decreased appetite—Thiotepa—sarcoma	0.000574	0.00323	CcSEcCtD
Toremifene—Menopausal symptoms—Epirubicin—sarcoma	0.000573	0.00322	CcSEcCtD
Toremifene—Thrombocytopenia—Vincristine—sarcoma	0.000573	0.00322	CcSEcCtD
Toremifene—Oedema—Mitoxantrone—sarcoma	0.00057	0.00321	CcSEcCtD
Toremifene—Gastrointestinal disorder—Thiotepa—sarcoma	0.00057	0.0032	CcSEcCtD
Toremifene—Decreased appetite—Dactinomycin—sarcoma	0.00057	0.0032	CcSEcCtD
Toremifene—Fatigue—Thiotepa—sarcoma	0.000569	0.0032	CcSEcCtD
Toremifene—Hyperhidrosis—Vincristine—sarcoma	0.000566	0.00318	CcSEcCtD
Toremifene—Fatigue—Dactinomycin—sarcoma	0.000565	0.00318	CcSEcCtD
Toremifene—Constipation—Thiotepa—sarcoma	0.000565	0.00317	CcSEcCtD
Toremifene—Pain—Thiotepa—sarcoma	0.000565	0.00317	CcSEcCtD
Toremifene—Back pain—Etoposide—sarcoma	0.000562	0.00316	CcSEcCtD
Toremifene—Pain—Dactinomycin—sarcoma	0.000561	0.00315	CcSEcCtD
Toremifene—Thrombocytopenia—Mitoxantrone—sarcoma	0.000558	0.00314	CcSEcCtD
Toremifene—Anorexia—Vincristine—sarcoma	0.000558	0.00314	CcSEcCtD
Toremifene—Cardiac failure—Epirubicin—sarcoma	0.000554	0.00312	CcSEcCtD
Toremifene—Skin disorder—Mitoxantrone—sarcoma	0.000554	0.00311	CcSEcCtD
Toremifene—Lethargy—Epirubicin—sarcoma	0.000552	0.0031	CcSEcCtD
Toremifene—Hyperhidrosis—Mitoxantrone—sarcoma	0.000551	0.0031	CcSEcCtD
Toremifene—Anorexia—Mitoxantrone—sarcoma	0.000544	0.00306	CcSEcCtD
Toremifene—Diplopia—Epirubicin—sarcoma	0.000541	0.00304	CcSEcCtD
Toremifene—Hot flush—Doxorubicin—sarcoma	0.000535	0.00301	CcSEcCtD
Toremifene—Affect lability—Epirubicin—sarcoma	0.000533	0.00299	CcSEcCtD
Toremifene—Menopausal symptoms—Doxorubicin—sarcoma	0.000531	0.00298	CcSEcCtD
Toremifene—Insomnia—Vincristine—sarcoma	0.00053	0.00298	CcSEcCtD
Toremifene—Vertigo—Etoposide—sarcoma	0.000522	0.00294	CcSEcCtD
Toremifene—Leukopenia—Etoposide—sarcoma	0.00052	0.00292	CcSEcCtD
Toremifene—Cardiac failure—Doxorubicin—sarcoma	0.000513	0.00288	CcSEcCtD
Toremifene—Mood swings—Epirubicin—sarcoma	0.000513	0.00288	CcSEcCtD
Toremifene—Lethargy—Doxorubicin—sarcoma	0.000511	0.00287	CcSEcCtD
Toremifene—Decreased appetite—Vincristine—sarcoma	0.000509	0.00286	CcSEcCtD
Toremifene—Ataxia—Epirubicin—sarcoma	0.000509	0.00286	CcSEcCtD
Toremifene—Dyspnoea—Mitoxantrone—sarcoma	0.000509	0.00286	CcSEcCtD
Toremifene—Gastrointestinal disorder—Vincristine—sarcoma	0.000506	0.00284	CcSEcCtD
Toremifene—Fatigue—Vincristine—sarcoma	0.000505	0.00284	CcSEcCtD
Toremifene—Constipation—Vincristine—sarcoma	0.000501	0.00281	CcSEcCtD
Toremifene—Pain—Vincristine—sarcoma	0.000501	0.00281	CcSEcCtD
Toremifene—Diplopia—Doxorubicin—sarcoma	0.000501	0.00281	CcSEcCtD
Toremifene—Liver function test abnormal—Epirubicin—sarcoma	0.0005	0.00281	CcSEcCtD
Toremifene—Decreased appetite—Mitoxantrone—sarcoma	0.000496	0.00279	CcSEcCtD
Toremifene—Chest pain—Etoposide—sarcoma	0.000495	0.00278	CcSEcCtD
Toremifene—Affect lability—Doxorubicin—sarcoma	0.000493	0.00277	CcSEcCtD
Toremifene—Fatigue—Mitoxantrone—sarcoma	0.000492	0.00276	CcSEcCtD
Toremifene—Unspecified disorder of skin and subcutaneous tissue—Etoposide—sarcoma	0.000492	0.00276	CcSEcCtD
Toremifene—ESR1—LKB1 signaling events—EZR—sarcoma	0.000491	0.0373	CbGpPWpGaD
Toremifene—Breast disorder—Epirubicin—sarcoma	0.000489	0.00275	CcSEcCtD
Toremifene—Pain—Mitoxantrone—sarcoma	0.000488	0.00274	CcSEcCtD
Toremifene—Constipation—Mitoxantrone—sarcoma	0.000488	0.00274	CcSEcCtD
Toremifene—Mood swings—Doxorubicin—sarcoma	0.000474	0.00267	CcSEcCtD
Toremifene—Asthenia—Thiotepa—sarcoma	0.000474	0.00266	CcSEcCtD
Toremifene—Ataxia—Doxorubicin—sarcoma	0.000471	0.00265	CcSEcCtD
Toremifene—Asthenia—Dactinomycin—sarcoma	0.00047	0.00264	CcSEcCtD
Toremifene—Pruritus—Thiotepa—sarcoma	0.000467	0.00263	CcSEcCtD
Toremifene—ESR1—FOXA1 transcription factor network—COL18A1—sarcoma	0.000467	0.0355	CbGpPWpGaD
Toremifene—Thrombocytopenia—Etoposide—sarcoma	0.000465	0.00261	CcSEcCtD
Toremifene—Liver function test abnormal—Doxorubicin—sarcoma	0.000462	0.0026	CcSEcCtD
Toremifene—Skin disorder—Etoposide—sarcoma	0.000461	0.00259	CcSEcCtD
Toremifene—Hyperhidrosis—Etoposide—sarcoma	0.000459	0.00258	CcSEcCtD
Toremifene—Angina pectoris—Epirubicin—sarcoma	0.000456	0.00256	CcSEcCtD
Toremifene—Breast disorder—Doxorubicin—sarcoma	0.000452	0.00254	CcSEcCtD
Toremifene—Anorexia—Etoposide—sarcoma	0.000452	0.00254	CcSEcCtD
Toremifene—ESR1—Signaling mediated by p38-alpha and p38-beta—MITF—sarcoma	0.000439	0.0333	CbGpPWpGaD
Toremifene—Dizziness—Thiotepa—sarcoma	0.000437	0.00245	CcSEcCtD
Toremifene—Weight increased—Epirubicin—sarcoma	0.000426	0.00239	CcSEcCtD
Toremifene—Dyspnoea—Etoposide—sarcoma	0.000423	0.00238	CcSEcCtD
Toremifene—Angina pectoris—Doxorubicin—sarcoma	0.000422	0.00237	CcSEcCtD
Toremifene—Asthenia—Vincristine—sarcoma	0.00042	0.00236	CcSEcCtD
Toremifene—Vomiting—Thiotepa—sarcoma	0.00042	0.00236	CcSEcCtD
Toremifene—Vomiting—Dactinomycin—sarcoma	0.000417	0.00234	CcSEcCtD
Toremifene—Rash—Thiotepa—sarcoma	0.000416	0.00234	CcSEcCtD
Toremifene—Dermatitis—Thiotepa—sarcoma	0.000416	0.00234	CcSEcCtD
Toremifene—Headache—Thiotepa—sarcoma	0.000414	0.00233	CcSEcCtD
Toremifene—Rash—Dactinomycin—sarcoma	0.000413	0.00232	CcSEcCtD
Toremifene—Decreased appetite—Etoposide—sarcoma	0.000412	0.00232	CcSEcCtD
Toremifene—Gastrointestinal disorder—Etoposide—sarcoma	0.00041	0.0023	CcSEcCtD
Toremifene—Asthenia—Mitoxantrone—sarcoma	0.000409	0.0023	CcSEcCtD
Toremifene—Fatigue—Etoposide—sarcoma	0.000409	0.0023	CcSEcCtD
Toremifene—Neuropathy peripheral—Epirubicin—sarcoma	0.000409	0.0023	CcSEcCtD
Toremifene—Jaundice—Epirubicin—sarcoma	0.000406	0.00228	CcSEcCtD
Toremifene—Pain—Etoposide—sarcoma	0.000406	0.00228	CcSEcCtD
Toremifene—Constipation—Etoposide—sarcoma	0.000406	0.00228	CcSEcCtD
Toremifene—Sweating—Epirubicin—sarcoma	0.0004	0.00225	CcSEcCtD
Toremifene—Hepatobiliary disease—Epirubicin—sarcoma	0.000394	0.00222	CcSEcCtD
Toremifene—Weight increased—Doxorubicin—sarcoma	0.000394	0.00221	CcSEcCtD
Toremifene—Nausea—Thiotepa—sarcoma	0.000392	0.0022	CcSEcCtD
Toremifene—Nausea—Dactinomycin—sarcoma	0.000389	0.00219	CcSEcCtD
Toremifene—Dizziness—Vincristine—sarcoma	0.000387	0.00218	CcSEcCtD
Toremifene—Neuropathy peripheral—Doxorubicin—sarcoma	0.000378	0.00213	CcSEcCtD
Toremifene—Jaundice—Doxorubicin—sarcoma	0.000376	0.00211	CcSEcCtD
Toremifene—Vomiting—Vincristine—sarcoma	0.000372	0.00209	CcSEcCtD
Toremifene—Sweating—Doxorubicin—sarcoma	0.00037	0.00208	CcSEcCtD
Toremifene—Rash—Vincristine—sarcoma	0.000369	0.00208	CcSEcCtD
Toremifene—Dermatitis—Vincristine—sarcoma	0.000369	0.00207	CcSEcCtD
Toremifene—Headache—Vincristine—sarcoma	0.000367	0.00206	CcSEcCtD
Toremifene—Hepatobiliary disease—Doxorubicin—sarcoma	0.000365	0.00205	CcSEcCtD
Toremifene—Vomiting—Mitoxantrone—sarcoma	0.000363	0.00204	CcSEcCtD
Toremifene—Visual impairment—Epirubicin—sarcoma	0.000361	0.00203	CcSEcCtD
Toremifene—Rash—Mitoxantrone—sarcoma	0.00036	0.00202	CcSEcCtD
Toremifene—Dermatitis—Mitoxantrone—sarcoma	0.000359	0.00202	CcSEcCtD
Toremifene—Headache—Mitoxantrone—sarcoma	0.000357	0.00201	CcSEcCtD
Toremifene—Eye disorder—Epirubicin—sarcoma	0.00035	0.00197	CcSEcCtD
Toremifene—Nausea—Vincristine—sarcoma	0.000348	0.00196	CcSEcCtD
Toremifene—ESR1—Validated nuclear estrogen receptor alpha network—COL18A1—sarcoma	0.000346	0.0263	CbGpPWpGaD
Toremifene—Asthenia—Etoposide—sarcoma	0.00034	0.00191	CcSEcCtD
Toremifene—Angiopathy—Epirubicin—sarcoma	0.00034	0.00191	CcSEcCtD
Toremifene—Nausea—Mitoxantrone—sarcoma	0.000339	0.0019	CcSEcCtD
Toremifene—Mediastinal disorder—Epirubicin—sarcoma	0.000337	0.0019	CcSEcCtD
Toremifene—Chills—Epirubicin—sarcoma	0.000336	0.00189	CcSEcCtD
Toremifene—Pruritus—Etoposide—sarcoma	0.000336	0.00189	CcSEcCtD
Toremifene—Arrhythmia—Epirubicin—sarcoma	0.000334	0.00188	CcSEcCtD
Toremifene—Visual impairment—Doxorubicin—sarcoma	0.000334	0.00188	CcSEcCtD
Toremifene—Alopecia—Epirubicin—sarcoma	0.000331	0.00186	CcSEcCtD
Toremifene—Mental disorder—Epirubicin—sarcoma	0.000328	0.00184	CcSEcCtD
Toremifene—Malnutrition—Epirubicin—sarcoma	0.000326	0.00183	CcSEcCtD
Toremifene—Eye disorder—Doxorubicin—sarcoma	0.000324	0.00182	CcSEcCtD
Toremifene—ESR1—Signaling mediated by p38-alpha and p38-beta—ATF1—sarcoma	0.000317	0.0241	CbGpPWpGaD
Toremifene—Back pain—Epirubicin—sarcoma	0.000315	0.00177	CcSEcCtD
Toremifene—Angiopathy—Doxorubicin—sarcoma	0.000314	0.00177	CcSEcCtD
Toremifene—Dizziness—Etoposide—sarcoma	0.000314	0.00176	CcSEcCtD
Toremifene—Mediastinal disorder—Doxorubicin—sarcoma	0.000312	0.00175	CcSEcCtD
Toremifene—Chills—Doxorubicin—sarcoma	0.000311	0.00175	CcSEcCtD
Toremifene—Arrhythmia—Doxorubicin—sarcoma	0.000309	0.00174	CcSEcCtD
Toremifene—Vision blurred—Epirubicin—sarcoma	0.000307	0.00173	CcSEcCtD
Toremifene—Alopecia—Doxorubicin—sarcoma	0.000306	0.00172	CcSEcCtD
Toremifene—Mental disorder—Doxorubicin—sarcoma	0.000303	0.00171	CcSEcCtD
Toremifene—Vomiting—Etoposide—sarcoma	0.000302	0.0017	CcSEcCtD
Toremifene—Malnutrition—Doxorubicin—sarcoma	0.000302	0.00169	CcSEcCtD
Toremifene—Rash—Etoposide—sarcoma	0.000299	0.00168	CcSEcCtD
Toremifene—Dermatitis—Etoposide—sarcoma	0.000299	0.00168	CcSEcCtD
Toremifene—Headache—Etoposide—sarcoma	0.000297	0.00167	CcSEcCtD
Toremifene—Vertigo—Epirubicin—sarcoma	0.000293	0.00165	CcSEcCtD
Toremifene—Leukopenia—Epirubicin—sarcoma	0.000292	0.00164	CcSEcCtD
Toremifene—Back pain—Doxorubicin—sarcoma	0.000292	0.00164	CcSEcCtD
Toremifene—Vision blurred—Doxorubicin—sarcoma	0.000284	0.0016	CcSEcCtD
Toremifene—Nausea—Etoposide—sarcoma	0.000282	0.00158	CcSEcCtD
Toremifene—Chest pain—Epirubicin—sarcoma	0.000277	0.00156	CcSEcCtD
Toremifene—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	0.000276	0.00155	CcSEcCtD
Toremifene—ESR1—Estrogen Receptor Pathway—JUN—sarcoma	0.000273	0.0207	CbGpPWpGaD
Toremifene—Vertigo—Doxorubicin—sarcoma	0.000271	0.00152	CcSEcCtD
Toremifene—Leukopenia—Doxorubicin—sarcoma	0.00027	0.00152	CcSEcCtD
Toremifene—Oedema—Epirubicin—sarcoma	0.000266	0.00149	CcSEcCtD
Toremifene—Nervous system disorder—Epirubicin—sarcoma	0.000261	0.00147	CcSEcCtD
Toremifene—Thrombocytopenia—Epirubicin—sarcoma	0.00026	0.00146	CcSEcCtD
Toremifene—Skin disorder—Epirubicin—sarcoma	0.000258	0.00145	CcSEcCtD
Toremifene—ESR1—Regulation of Telomerase—WT1—sarcoma	0.000258	0.0196	CbGpPWpGaD
Toremifene—Hyperhidrosis—Epirubicin—sarcoma	0.000257	0.00144	CcSEcCtD
Toremifene—Chest pain—Doxorubicin—sarcoma	0.000257	0.00144	CcSEcCtD
Toremifene—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	0.000255	0.00143	CcSEcCtD
Toremifene—Anorexia—Epirubicin—sarcoma	0.000254	0.00142	CcSEcCtD
Toremifene—Oedema—Doxorubicin—sarcoma	0.000246	0.00138	CcSEcCtD
Toremifene—Nervous system disorder—Doxorubicin—sarcoma	0.000241	0.00136	CcSEcCtD
Toremifene—ESR1—Regulation of nuclear SMAD2/3 signaling—MYOD1—sarcoma	0.000241	0.0183	CbGpPWpGaD
Toremifene—Thrombocytopenia—Doxorubicin—sarcoma	0.000241	0.00135	CcSEcCtD
Toremifene—Insomnia—Epirubicin—sarcoma	0.000241	0.00135	CcSEcCtD
Toremifene—ESR1—Estrogen signaling pathway—CREB1—sarcoma	0.00024	0.0183	CbGpPWpGaD
Toremifene—Skin disorder—Doxorubicin—sarcoma	0.000239	0.00134	CcSEcCtD
Toremifene—Hyperhidrosis—Doxorubicin—sarcoma	0.000238	0.00134	CcSEcCtD
Toremifene—Dyspnoea—Epirubicin—sarcoma	0.000237	0.00133	CcSEcCtD
Toremifene—Anorexia—Doxorubicin—sarcoma	0.000235	0.00132	CcSEcCtD
Toremifene—Decreased appetite—Epirubicin—sarcoma	0.000231	0.0013	CcSEcCtD
Toremifene—Gastrointestinal disorder—Epirubicin—sarcoma	0.00023	0.00129	CcSEcCtD
Toremifene—Fatigue—Epirubicin—sarcoma	0.000229	0.00129	CcSEcCtD
Toremifene—Constipation—Epirubicin—sarcoma	0.000227	0.00128	CcSEcCtD
Toremifene—Pain—Epirubicin—sarcoma	0.000227	0.00128	CcSEcCtD
Toremifene—Insomnia—Doxorubicin—sarcoma	0.000223	0.00125	CcSEcCtD
Toremifene—Dyspnoea—Doxorubicin—sarcoma	0.000219	0.00123	CcSEcCtD
Toremifene—ESR1—Plasma membrane estrogen receptor signaling—IGF1R—sarcoma	0.000219	0.0167	CbGpPWpGaD
Toremifene—Decreased appetite—Doxorubicin—sarcoma	0.000214	0.0012	CcSEcCtD
Toremifene—Gastrointestinal disorder—Doxorubicin—sarcoma	0.000212	0.00119	CcSEcCtD
Toremifene—Fatigue—Doxorubicin—sarcoma	0.000212	0.00119	CcSEcCtD
Toremifene—Pain—Doxorubicin—sarcoma	0.00021	0.00118	CcSEcCtD
Toremifene—Constipation—Doxorubicin—sarcoma	0.00021	0.00118	CcSEcCtD
Toremifene—Asthenia—Epirubicin—sarcoma	0.000191	0.00107	CcSEcCtD
Toremifene—Pruritus—Epirubicin—sarcoma	0.000188	0.00106	CcSEcCtD
Toremifene—CYP1A1—Melatonin metabolism and effects—FOXO1—sarcoma	0.000182	0.0139	CbGpPWpGaD
Toremifene—ESR1—Leptin signaling pathway—PLCG1—sarcoma	0.000181	0.0138	CbGpPWpGaD
Toremifene—CYP1A1—Estrogen Receptor Pathway—JUN—sarcoma	0.000181	0.0137	CbGpPWpGaD
Toremifene—ESR1—mammary gland—sarcoma	0.000177	0.0695	CbGeAlD
Toremifene—Asthenia—Doxorubicin—sarcoma	0.000177	0.000992	CcSEcCtD
Toremifene—Dizziness—Epirubicin—sarcoma	0.000176	0.000988	CcSEcCtD
Toremifene—Pruritus—Doxorubicin—sarcoma	0.000174	0.000978	CcSEcCtD
Toremifene—ESR1—Estrogen signaling pathway—JUN—sarcoma	0.000173	0.0131	CbGpPWpGaD
Toremifene—ESR1—Signaling mediated by p38-alpha and p38-beta—CREB1—sarcoma	0.000172	0.0131	CbGpPWpGaD
Toremifene—Vomiting—Epirubicin—sarcoma	0.000169	0.00095	CcSEcCtD
Toremifene—Rash—Epirubicin—sarcoma	0.000168	0.000942	CcSEcCtD
Toremifene—Dermatitis—Epirubicin—sarcoma	0.000168	0.000942	CcSEcCtD
Toremifene—Headache—Epirubicin—sarcoma	0.000167	0.000936	CcSEcCtD
Toremifene—Dizziness—Doxorubicin—sarcoma	0.000163	0.000915	CcSEcCtD
Toremifene—Nausea—Epirubicin—sarcoma	0.000158	0.000888	CcSEcCtD
Toremifene—Vomiting—Doxorubicin—sarcoma	0.000156	0.000879	CcSEcCtD
Toremifene—Rash—Doxorubicin—sarcoma	0.000155	0.000872	CcSEcCtD
Toremifene—Dermatitis—Doxorubicin—sarcoma	0.000155	0.000871	CcSEcCtD
Toremifene—Headache—Doxorubicin—sarcoma	0.000154	0.000866	CcSEcCtD
Toremifene—ESR1—ATF-2 transcription factor network—PDGFRA—sarcoma	0.000153	0.0116	CbGpPWpGaD
Toremifene—Nausea—Doxorubicin—sarcoma	0.000146	0.000821	CcSEcCtD
Toremifene—ESR1—LKB1 signaling events—CREB1—sarcoma	0.000146	0.0111	CbGpPWpGaD
Toremifene—ABCB1—HIF-1-alpha transcription factor network—NPM1—sarcoma	0.000145	0.011	CbGpPWpGaD
Toremifene—ESR1—Plasma membrane estrogen receptor signaling—MMP2—sarcoma	0.000141	0.0107	CbGpPWpGaD
Toremifene—ESR1—FOXM1 transcription factor network—MMP2—sarcoma	0.000138	0.0105	CbGpPWpGaD
Toremifene—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—FLT1—sarcoma	0.000137	0.0104	CbGpPWpGaD
Toremifene—ABCB1—Constitutive Androstane Receptor Pathway—FOXO1—sarcoma	0.000135	0.0102	CbGpPWpGaD
Toremifene—ESR1—Leptin signaling pathway—FOXO1—sarcoma	0.000129	0.00978	CbGpPWpGaD
Toremifene—ESR1—myometrium—sarcoma	0.000126	0.0493	CbGeAlD
Toremifene—ESR1—Signaling mediated by p38-alpha and p38-beta—JUN—sarcoma	0.000124	0.00939	CbGpPWpGaD
Toremifene—ESR1—embryo—sarcoma	0.000121	0.0474	CbGeAlD
Toremifene—ESR1—Regulation of nuclear SMAD2/3 signaling—FOXO1—sarcoma	0.000121	0.0092	CbGpPWpGaD
Toremifene—CYP1A2—Melatonin metabolism and effects—FOXO1—sarcoma	0.000116	0.00884	CbGpPWpGaD
Toremifene—CYP1A2—Estrogen Receptor Pathway—JUN—sarcoma	0.000115	0.00876	CbGpPWpGaD
Toremifene—ESR1—ATF-2 transcription factor network—CREB1—sarcoma	0.000113	0.0086	CbGpPWpGaD
Toremifene—ESR1—Integrated Pancreatic Cancer Pathway—WT1—sarcoma	0.000113	0.00858	CbGpPWpGaD
Toremifene—ESR1—hematopoietic system—sarcoma	0.000108	0.0423	CbGeAlD
Toremifene—ESR1—FOXM1 transcription factor network—CCND1—sarcoma	0.000107	0.00813	CbGpPWpGaD
Toremifene—ESR1—ATF-2 transcription factor network—MMP2—sarcoma	0.000105	0.008	CbGpPWpGaD
Toremifene—ESR1—connective tissue—sarcoma	0.000104	0.0408	CbGeAlD
Toremifene—ESR1—FOXA1 transcription factor network—JUN—sarcoma	0.000103	0.00782	CbGpPWpGaD
Toremifene—ABCB1—HIF-1-alpha transcription factor network—CXCR4—sarcoma	0.000102	0.00776	CbGpPWpGaD
Toremifene—ESR1—AP-1 transcription factor network—CREB1—sarcoma	9.87e-05	0.0075	CbGpPWpGaD
Toremifene—ESR1—Integrated Breast Cancer Pathway—ATF1—sarcoma	9.85e-05	0.00748	CbGpPWpGaD
Toremifene—ESR1—Plasma membrane estrogen receptor signaling—SRC—sarcoma	9.76e-05	0.00742	CbGpPWpGaD
Toremifene—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRB—sarcoma	9.56e-05	0.00726	CbGpPWpGaD
Toremifene—ESR1—smooth muscle tissue—sarcoma	9.52e-05	0.0373	CbGeAlD
Toremifene—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRA—sarcoma	9.41e-05	0.00715	CbGpPWpGaD
Toremifene—ESR1—Plasma membrane estrogen receptor signaling—NRAS—sarcoma	9.39e-05	0.00714	CbGpPWpGaD
Toremifene—ESR1—Leptin signaling pathway—CREB1—sarcoma	9.34e-05	0.0071	CbGpPWpGaD
Toremifene—ESR1—Aryl Hydrocarbon Receptor—SRC—sarcoma	8.9e-05	0.00677	CbGpPWpGaD
Toremifene—ESR1—Regulation of nuclear SMAD2/3 signaling—CREB1—sarcoma	8.78e-05	0.00667	CbGpPWpGaD
Toremifene—ESR1—Aryl Hydrocarbon Receptor—VEGFA—sarcoma	8.67e-05	0.00659	CbGpPWpGaD
Toremifene—ESR1—FOXM1 transcription factor network—MYC—sarcoma	8.58e-05	0.00652	CbGpPWpGaD
Toremifene—ESR1—Aryl Hydrocarbon Receptor—NRAS—sarcoma	8.57e-05	0.00651	CbGpPWpGaD
Toremifene—ESR1—LKB1 signaling events—MYC—sarcoma	8.42e-05	0.0064	CbGpPWpGaD
Toremifene—CYP1A2—hematopoietic system—sarcoma	8.33e-05	0.0326	CbGeAlD
Toremifene—CYP3A4—Constitutive Androstane Receptor Pathway—FOXO1—sarcoma	8.29e-05	0.0063	CbGpPWpGaD
Toremifene—CYP1A1—hematopoietic system—sarcoma	8.22e-05	0.0322	CbGeAlD
Toremifene—ESR1—uterus—sarcoma	8.17e-05	0.032	CbGeAlD
Toremifene—ESR1—Signaling mediated by p38-alpha and p38-beta—TP53—sarcoma	8.15e-05	0.0062	CbGpPWpGaD
Toremifene—ESR1—ATF-2 transcription factor network—CCND1—sarcoma	8.15e-05	0.0062	CbGpPWpGaD
Toremifene—ESR1—ATF-2 transcription factor network—JUN—sarcoma	8.13e-05	0.00618	CbGpPWpGaD
Toremifene—ESR1—Plasma membrane estrogen receptor signaling—KRAS—sarcoma	8.08e-05	0.00614	CbGpPWpGaD
Toremifene—ESR1—Aryl Hydrocarbon Receptor—MYC—sarcoma	7.98e-05	0.00607	CbGpPWpGaD
Toremifene—ESR1—Aryl Hydrocarbon Receptor—EGFR—sarcoma	7.8e-05	0.00593	CbGpPWpGaD
Toremifene—ESR1—Validated nuclear estrogen receptor alpha network—CCND1—sarcoma	7.64e-05	0.00581	CbGpPWpGaD
Toremifene—ESR1—Validated nuclear estrogen receptor alpha network—JUN—sarcoma	7.62e-05	0.00579	CbGpPWpGaD
Toremifene—ESR1—lymphoid tissue—sarcoma	7.61e-05	0.0298	CbGeAlD
Toremifene—CYP1A1—Tryptophan metabolism—MDM2—sarcoma	7.57e-05	0.00575	CbGpPWpGaD
Toremifene—ESR1—Regulation of Telomerase—IL2—sarcoma	7.46e-05	0.00567	CbGpPWpGaD
Toremifene—ESR1—Aryl Hydrocarbon Receptor—KRAS—sarcoma	7.37e-05	0.0056	CbGpPWpGaD
Toremifene—ESR1—Integrated Breast Cancer Pathway—FOXO1—sarcoma	7.35e-05	0.00559	CbGpPWpGaD
Toremifene—ESR1—Signaling by ERBB4—FOXO1—sarcoma	7.31e-05	0.00556	CbGpPWpGaD
Toremifene—ESR1—Signaling by ERBB4—PDGFRB—sarcoma	7.3e-05	0.00555	CbGpPWpGaD
Toremifene—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—sarcoma	7.29e-05	0.00554	CbGpPWpGaD
Toremifene—ESR1—AP-1 transcription factor network—IL2—sarcoma	7.29e-05	0.00554	CbGpPWpGaD
Toremifene—ESR1—Regulation of Telomerase—CCND1—sarcoma	7.28e-05	0.00553	CbGpPWpGaD
Toremifene—ESR1—Regulation of Telomerase—JUN—sarcoma	7.26e-05	0.00552	CbGpPWpGaD
Toremifene—ESR1—Signaling by ERBB4—PDGFRA—sarcoma	7.19e-05	0.00546	CbGpPWpGaD
Toremifene—CYP1A1—skin of body—sarcoma	7.15e-05	0.028	CbGeAlD
Toremifene—ESR1—AP-1 transcription factor network—CCND1—sarcoma	7.11e-05	0.0054	CbGpPWpGaD
Toremifene—ESR1—AP-1 transcription factor network—JUN—sarcoma	7.09e-05	0.00539	CbGpPWpGaD
Toremifene—ESR1—AP-1 transcription factor network—CTNNB1—sarcoma	7.04e-05	0.00535	CbGpPWpGaD
Toremifene—ESR1—LKB1 signaling events—TP53—sarcoma	6.92e-05	0.00526	CbGpPWpGaD
Toremifene—ESR1—Plasma membrane estrogen receptor signaling—HRAS—sarcoma	6.87e-05	0.00522	CbGpPWpGaD
Toremifene—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL2—sarcoma	6.76e-05	0.00514	CbGpPWpGaD
Toremifene—ESR1—Leptin signaling pathway—CCND1—sarcoma	6.73e-05	0.00511	CbGpPWpGaD
Toremifene—CYP1A1—Aryl Hydrocarbon Receptor Pathway—JUN—sarcoma	6.58e-05	0.005	CbGpPWpGaD
Toremifene—ABCB1—Allograft Rejection—PDGFRA—sarcoma	6.42e-05	0.00488	CbGpPWpGaD
Toremifene—ESR1—Regulation of nuclear SMAD2/3 signaling—JUN—sarcoma	6.31e-05	0.0048	CbGpPWpGaD
Toremifene—ESR1—Aryl Hydrocarbon Receptor—HRAS—sarcoma	6.27e-05	0.00476	CbGpPWpGaD
Toremifene—CYP1A1—cardiac atrium—sarcoma	6.24e-05	0.0244	CbGeAlD
Toremifene—CYP1A1—uterus—sarcoma	6.21e-05	0.0243	CbGeAlD
Toremifene—ESR1—Validated nuclear estrogen receptor alpha network—MYC—sarcoma	6.13e-05	0.00466	CbGpPWpGaD
Toremifene—CYP3A4—hematopoietic system—sarcoma	6.03e-05	0.0236	CbGeAlD
Toremifene—ESR1—Leptin signaling pathway—SRC—sarcoma	6.02e-05	0.00458	CbGpPWpGaD
Toremifene—ESR1—Integrated Pancreatic Cancer Pathway—PDGFRA—sarcoma	5.99e-05	0.00455	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—sarcoma	5.97e-05	0.00454	CbGpPWpGaD
Toremifene—ESR1—testis—sarcoma	5.92e-05	0.0232	CbGeAlD
Toremifene—CYP1A1—Aryl Hydrocarbon Receptor—SRC—sarcoma	5.9e-05	0.00448	CbGpPWpGaD
Toremifene—CYP1A1—Aryl Hydrocarbon Receptor Pathway—SRC—sarcoma	5.9e-05	0.00448	CbGpPWpGaD
Toremifene—ESR1—Regulation of Telomerase—MYC—sarcoma	5.84e-05	0.00444	CbGpPWpGaD
Toremifene—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—sarcoma	5.74e-05	0.00437	CbGpPWpGaD
Toremifene—ESR1—Regulation of Telomerase—EGFR—sarcoma	5.71e-05	0.00434	CbGpPWpGaD
Toremifene—ESR1—AP-1 transcription factor network—MYC—sarcoma	5.7e-05	0.00433	CbGpPWpGaD
Toremifene—CYP1A1—Aryl Hydrocarbon Receptor—NRAS—sarcoma	5.67e-05	0.00431	CbGpPWpGaD
Toremifene—ESR1—liver—sarcoma	5.6e-05	0.0219	CbGeAlD
Toremifene—ESR1—Signaling by ERBB4—KIT—sarcoma	5.57e-05	0.00424	CbGpPWpGaD
Toremifene—ABCB1—HIF-1-alpha transcription factor network—CREB1—sarcoma	5.47e-05	0.00416	CbGpPWpGaD
Toremifene—ESR1—Integrated Breast Cancer Pathway—CREB1—sarcoma	5.33e-05	0.00405	CbGpPWpGaD
Toremifene—ESR1—Signaling by ERBB4—CREB1—sarcoma	5.31e-05	0.00403	CbGpPWpGaD
Toremifene—CYP1A1—Aryl Hydrocarbon Receptor—MYC—sarcoma	5.29e-05	0.00402	CbGpPWpGaD
Toremifene—CYP1A1—Aryl Hydrocarbon Receptor—EGFR—sarcoma	5.17e-05	0.00393	CbGpPWpGaD
Toremifene—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—sarcoma	5.17e-05	0.00393	CbGpPWpGaD
Toremifene—ESR1—Regulation of nuclear SMAD2/3 signaling—MYC—sarcoma	5.07e-05	0.00386	CbGpPWpGaD
Toremifene—ABCB1—myometrium—sarcoma	4.97e-05	0.0195	CbGeAlD
Toremifene—CYP1A1—Aryl Hydrocarbon Receptor—KRAS—sarcoma	4.88e-05	0.00371	CbGpPWpGaD
Toremifene—CYP1A2—Tryptophan metabolism—MDM2—sarcoma	4.82e-05	0.00367	CbGpPWpGaD
Toremifene—ABCB1—embryo—sarcoma	4.78e-05	0.0187	CbGeAlD
Toremifene—ESR1—Gene Expression—FUS—sarcoma	4.7e-05	0.00357	CbGpPWpGaD
Toremifene—ESR1—AP-1 transcription factor network—TP53—sarcoma	4.68e-05	0.00356	CbGpPWpGaD
Toremifene—ABCB1—seminal vesicle—sarcoma	4.49e-05	0.0176	CbGeAlD
Toremifene—ESR1—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	4.42e-05	0.00336	CbGpPWpGaD
Toremifene—ESR1—Integrated Breast Cancer Pathway—MDM2—sarcoma	4.41e-05	0.00335	CbGpPWpGaD
Toremifene—ESR1—Signaling by ERBB4—MDM2—sarcoma	4.39e-05	0.00334	CbGpPWpGaD
Toremifene—CYP1A2—liver—sarcoma	4.32e-05	0.0169	CbGeAlD
Toremifene—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—sarcoma	4.31e-05	0.00328	CbGpPWpGaD
Toremifene—ESR1—lymph node—sarcoma	4.29e-05	0.0168	CbGeAlD
Toremifene—ABCB1—hematopoietic system—sarcoma	4.27e-05	0.0167	CbGeAlD
Toremifene—CYP1A1—liver—sarcoma	4.26e-05	0.0167	CbGeAlD
Toremifene—ESR1—Leptin signaling pathway—HRAS—sarcoma	4.24e-05	0.00322	CbGpPWpGaD
Toremifene—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—sarcoma	4.19e-05	0.00319	CbGpPWpGaD
Toremifene—CYP1A1—Aryl Hydrocarbon Receptor—HRAS—sarcoma	4.15e-05	0.00316	CbGpPWpGaD
Toremifene—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—sarcoma	4.01e-05	0.00305	CbGpPWpGaD
Toremifene—ABCB1—HIF-1-alpha transcription factor network—JUN—sarcoma	3.93e-05	0.00299	CbGpPWpGaD
Toremifene—ESR1—Integrated Breast Cancer Pathway—CCND1—sarcoma	3.84e-05	0.00292	CbGpPWpGaD
Toremifene—ESR1—Integrated Breast Cancer Pathway—JUN—sarcoma	3.84e-05	0.00292	CbGpPWpGaD
Toremifene—ESR1—Integrated Breast Cancer Pathway—CTNNB1—sarcoma	3.81e-05	0.00289	CbGpPWpGaD
Toremifene—CYP1A2—Aryl Hydrocarbon Receptor—SRC—sarcoma	3.76e-05	0.00286	CbGpPWpGaD
Toremifene—CYP1A2—Aryl Hydrocarbon Receptor Pathway—SRC—sarcoma	3.76e-05	0.00286	CbGpPWpGaD
Toremifene—CYP3A4—Tryptophan metabolism—MDM2—sarcoma	3.72e-05	0.00283	CbGpPWpGaD
Toremifene—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—sarcoma	3.66e-05	0.00278	CbGpPWpGaD
Toremifene—ESR1—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	3.66e-05	0.00278	CbGpPWpGaD
Toremifene—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—sarcoma	3.62e-05	0.00275	CbGpPWpGaD
Toremifene—ABCB1—Allograft Rejection—IL2—sarcoma	3.5e-05	0.00266	CbGpPWpGaD
Toremifene—ABCB1—HIF-1-alpha transcription factor network—VEGFA—sarcoma	3.44e-05	0.00261	CbGpPWpGaD
Toremifene—CYP1A2—Aryl Hydrocarbon Receptor—MYC—sarcoma	3.37e-05	0.00256	CbGpPWpGaD
Toremifene—ESR1—Integrated Breast Cancer Pathway—VEGFA—sarcoma	3.35e-05	0.00255	CbGpPWpGaD
Toremifene—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—sarcoma	3.3e-05	0.00251	CbGpPWpGaD
Toremifene—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—sarcoma	3.3e-05	0.00251	CbGpPWpGaD
Toremifene—ESR1—Signaling by ERBB4—NRAS—sarcoma	3.29e-05	0.0025	CbGpPWpGaD
Toremifene—CYP1A1—lymph node—sarcoma	3.27e-05	0.0128	CbGeAlD
Toremifene—ABCB1—uterus—sarcoma	3.22e-05	0.0126	CbGeAlD
Toremifene—ESR1—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	3.18e-05	0.00242	CbGpPWpGaD
Toremifene—ESR1—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	3.18e-05	0.00242	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—PDGFRA—sarcoma	3.17e-05	0.00241	CbGpPWpGaD
Toremifene—ESR1—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	3.15e-05	0.0024	CbGpPWpGaD
Toremifene—CYP3A4—liver—sarcoma	3.12e-05	0.0122	CbGeAlD
Toremifene—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—sarcoma	3.11e-05	0.00237	CbGpPWpGaD
Toremifene—ESR1—Integrated Breast Cancer Pathway—MYC—sarcoma	3.08e-05	0.00234	CbGpPWpGaD
Toremifene—ESR1—Integrated Breast Cancer Pathway—EGFR—sarcoma	3.02e-05	0.00229	CbGpPWpGaD
Toremifene—ABCB1—lymphoid tissue—sarcoma	3.01e-05	0.0118	CbGeAlD
Toremifene—ESR1—Signaling by ERBB4—EGFR—sarcoma	3e-05	0.00228	CbGpPWpGaD
Toremifene—ABCB1—Allograft Rejection—VEGFA—sarcoma	2.98e-05	0.00226	CbGpPWpGaD
Toremifene—ESR1—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	2.85e-05	0.00217	CbGpPWpGaD
Toremifene—ESR1—Integrated Breast Cancer Pathway—KRAS—sarcoma	2.85e-05	0.00217	CbGpPWpGaD
Toremifene—ESR1—Signaling by ERBB4—KRAS—sarcoma	2.83e-05	0.00215	CbGpPWpGaD
Toremifene—ESR1—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	2.78e-05	0.00211	CbGpPWpGaD
Toremifene—ABCB1—bone marrow—sarcoma	2.74e-05	0.0107	CbGeAlD
Toremifene—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—sarcoma	2.65e-05	0.00201	CbGpPWpGaD
Toremifene—ESR1—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	2.55e-05	0.00194	CbGpPWpGaD
Toremifene—ESR1—Integrated Breast Cancer Pathway—TP53—sarcoma	2.53e-05	0.00192	CbGpPWpGaD
Toremifene—ESR1—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	2.5e-05	0.0019	CbGpPWpGaD
Toremifene—ESR1—Signaling by ERBB4—HRAS—sarcoma	2.41e-05	0.00183	CbGpPWpGaD
Toremifene—ESR1—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	2.36e-05	0.00179	CbGpPWpGaD
Toremifene—ABCB1—testis—sarcoma	2.34e-05	0.00916	CbGeAlD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	2.34e-05	0.00178	CbGpPWpGaD
Toremifene—ABCB1—liver—sarcoma	2.21e-05	0.00866	CbGeAlD
Toremifene—ESR1—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	2.1e-05	0.00159	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—TLE1—sarcoma	2.01e-05	0.00153	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	1.93e-05	0.00147	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—VEGFC—sarcoma	1.7e-05	0.00129	CbGpPWpGaD
Toremifene—ABCB1—lymph node—sarcoma	1.7e-05	0.00664	CbGeAlD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	1.69e-05	0.00128	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	1.68e-05	0.00128	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	1.67e-05	0.00127	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	1.51e-05	0.00115	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	1.47e-05	0.00112	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—FLT1—sarcoma	1.36e-05	0.00103	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	1.35e-05	0.00103	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—PLCG1—sarcoma	1.34e-05	0.00102	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	1.32e-05	0.001	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—CXCR4—sarcoma	1.28e-05	0.000975	CbGpPWpGaD
Toremifene—ESR1—Generic Transcription Pathway—MYC—sarcoma	1.27e-05	0.000965	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—ATF1—sarcoma	1.27e-05	0.000964	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	1.25e-05	0.000949	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—ENO2—sarcoma	1.25e-05	0.000948	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—HBA1—sarcoma	1.24e-05	0.000942	CbGpPWpGaD
Toremifene—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	1.11e-05	0.000844	CbGpPWpGaD
Toremifene—CYP1A1—Metabolism—PLCG1—sarcoma	1.06e-05	0.000804	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—ENO2—sarcoma	9.96e-06	0.000757	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—IGF1R—sarcoma	9.95e-06	0.000757	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—HBA1—sarcoma	9.9e-06	0.000752	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—FOXO1—sarcoma	9.48e-06	0.00072	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—PDGFRB—sarcoma	9.46e-06	0.000719	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—PDGFRA—sarcoma	9.31e-06	0.000708	CbGpPWpGaD
Toremifene—ABCB1—Metabolism—PLCG1—sarcoma	8.45e-06	0.000642	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—ENO2—sarcoma	7.95e-06	0.000604	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—HBA1—sarcoma	7.9e-06	0.0006	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—KDR—sarcoma	7.84e-06	0.000596	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—KIT—sarcoma	7.22e-06	0.000549	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—CREB1—sarcoma	6.87e-06	0.000522	CbGpPWpGaD
Toremifene—CYP1A2—Metabolism—PLCG1—sarcoma	6.75e-06	0.000513	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—ENO2—sarcoma	6.14e-06	0.000466	CbGpPWpGaD
Toremifene—ESR1—Gene Expression—MYC—sarcoma	6.11e-06	0.000464	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—HBA1—sarcoma	6.1e-06	0.000463	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—MDM2—sarcoma	5.69e-06	0.000432	CbGpPWpGaD
Toremifene—CYP3A4—Metabolism—PLCG1—sarcoma	5.21e-06	0.000396	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—IL2—sarcoma	5.08e-06	0.000386	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—CCND1—sarcoma	4.95e-06	0.000376	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—JUN—sarcoma	4.94e-06	0.000376	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—CTNNB1—sarcoma	4.9e-06	0.000373	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—SRC—sarcoma	4.43e-06	0.000337	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—VEGFA—sarcoma	4.32e-06	0.000328	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—NRAS—sarcoma	4.26e-06	0.000324	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—MYC—sarcoma	3.97e-06	0.000302	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—EGFR—sarcoma	3.89e-06	0.000295	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—KRAS—sarcoma	3.67e-06	0.000279	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—TP53—sarcoma	3.26e-06	0.000248	CbGpPWpGaD
Toremifene—ESR1—Signaling Pathways—HRAS—sarcoma	3.12e-06	0.000237	CbGpPWpGaD
